U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H37N5O9.4Na
Molecular Weight 799.6876
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALAPORFIN SODIUM

SMILES

[Na+].[Na+].[Na+].[Na+].CCC1=C(C)C2=CC3=C(C=C)C(C)=C(N3)C=C4N=C([C@@H](CCC([O-])=O)[C@@H]4C)C(CC(=O)N[C@@H](CC([O-])=O)C([O-])=O)=C5NC(=CC1=N2)C(C)=C5C([O-])=O

InChI

InChIKey=KPALSRNVSRWOPA-YJFNSWLASA-J
InChI=1S/C38H41N5O9.4Na/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24;;;;/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52);;;;/q;4*+1/p-4/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-;;;;/t18-,22-,30-;;;;/m0..../s1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C38H35N5O9
Molecular Weight 705.7126
Charge -4
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). Talaporfin is injected into tumors and other regret tissues where it accumulates. It’s activated with light emitting diodes (LED). It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and glioma and marketed as Laserphyrin. Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of talaporfin sodium-mediated photodynamic therapy on cell death modalities in human glioblastoma T98G cells.
2014
Patents

Patents

JP2005524461A
2

Sample Use Guides

In Vivo Use Guide
single intravenous injection of talaporfin sodium (40 mg/m(2)) was administered 1 day before resection of the neoplasm
Route of Administration: Intravenous
In Vitro Use Guide
combination of 30 µg/mL NPe6 (talaporfin sodium) with 5 J/cm(2) laser is the best treatment condition for inducing an increase in apoptotic cells while keeping rate of necrotic cell death low
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:05 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:05 GMT 2025
Record UNII
L63605PZ70
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALAPORFIN SODIUM
JAN   MART.   USAN   WHO-DD  
USAN  
Official Name English
TALAPORFIN TETRASODIUM SALT
MI  
Preferred Name English
ME-2906
Code English
Tetrasodium (2S)-2-[[[(7S,8S)-3-carboxylato-7-(2-carboxylatoethyl)-13-ethenyl-18-ethyl-2,8,12,17-tetramethyl-7,8-dihydroporphyrin-5-yl]acetyl]amino]butanedioate
Common Name English
TALAPORFIN SODIUM [USAN]
Common Name English
ME 2906
Code English
LS-11
Code English
TALAPORFIN SODIUM [MART.]
Common Name English
TALAPORFIN TETRASODIUM SALT [MI]
Common Name English
TALAPORFIN SODIUM [JAN]
Common Name English
Talaporfin sodium [WHO-DD]
Common Name English
L-ASPARTIC ACID, N-(((7S,8S)-3-CARBOXY-7-(2-CARBOXYETHYL)-13-ETHENYL-18-ETHYL-7,8-DIHYDRO-2,8,12,17-TETRAMETHYL-21H,23H-PORPHIN-5-YL)ACETYL)-, TETRASODIUM SALT
Common Name English
LASERPHYRIN
Brand Name English
TAPORFIN SODIUM
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1420
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C26675
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
CAS
220201-34-3
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
MERCK INDEX
m10436
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB05918
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
USAN
OO-19
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
JAPANESE REVIEW
LASERPHYRIN
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY APPROVED MAY 2015
SMS_ID
300000044499
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
FDA UNII
L63605PZ70
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL2111186
Created by admin on Mon Mar 31 18:10:05 GMT 2025 , Edited by admin on Mon Mar 31 18:10:05 GMT 2025
PRIMARY
Related Record Type Details
Structure of TALAPORFIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966